Sambrinvest
Sambrinvest S.A. is a private equity and venture capital firm located in Gosselies, Belgium, established in 1985. The firm specializes in direct and fund of funds investments, focusing on small and medium-sized enterprises primarily in the Charleroi Sud-Hainaut and Thuin districts. Sambrinvest targets various sectors including agri-food, audiovisual, gaming, automotive, biotechnology, pharmaceuticals, construction, digital technology, environmental solutions, alternative energy, manufacturing, and real estate, while excluding retail, hospitality, and banking. The firm typically invests through minority stakes, subordinated loans, and other financial instruments, with investment amounts generally not exceeding €1.25 million in companies with revenues below €50 million. Sambrinvest is recognized as an active venture capital player in its region and remains open to opportunities in additional sectors.
Aerospacelab
Series B in 2022
Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacture of small satellites equipped with advanced sensors. The company focuses on creating satellite imagery technology that captures high-resolution optical data, allowing for frequent data collection. In addition to satellite production, Aerospacelab develops tools that utilize artificial intelligence and machine learning to automate various tasks, facilitating processes such as surveying and monitoring. This innovative approach enables customers to efficiently analyze substantial volumes of data and optimize the extraction of valuable insights from the information gathered.
PDC*line Pharma
Series B in 2021
PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, focused on developing innovative active immunotherapies for cancer. The company specializes in a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line), which are loaded with cancer-specific antigens to stimulate a robust immune response. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, the company emerged from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. PDC*line Pharma aims to enhance cancer treatment efficacy by producing potent and scalable PDC lines that can boost antitumor responses, including the activation of neoantigens and specific cytotoxic T-cells, offering a more effective alternative to conventional vaccines.
EsoBiotec
Seed Round in 2021
EsoBiotec is a Belgian biotechnology company dedicated to the discovery and development of novel cancer therapies. The firm focuses on empowering the human body to combat cancer through in vivo cell engineering. By creating innovative immunotherapies, EsoBiotec aims to provide cost-effective drugs and therapeutics that enhance accessibility, ensuring that patients can receive essential cancer treatments at lower costs.
ExeVir Bio
Series A in 2020
ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.
PDC*line Pharma
Series B in 2020
PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, focused on developing innovative active immunotherapies for cancer. The company specializes in a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line), which are loaded with cancer-specific antigens to stimulate a robust immune response. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, the company emerged from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. PDC*line Pharma aims to enhance cancer treatment efficacy by producing potent and scalable PDC lines that can boost antitumor responses, including the activation of neoantigens and specific cytotoxic T-cells, offering a more effective alternative to conventional vaccines.
Utopix Pictures
Seed Round in 2019
Utopix Pictures SA is a Belgium-based company founded in 2015 that operates a platform designed to connect users with professionals in the photography, film, and imaging sectors. The company aims to simplify the process of finding the right photographer or videographer to meet specific project needs. By leveraging a network of skilled professionals, Utopix Pictures assists clients in transforming their ideas into compelling visual content efficiently and effectively.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.